MGI Tech

Illumina said it plans to pursue a permanent injunction against BGI in the UK until the four patents expire — three in 2023 and one in 2027.

In their complaint the plaintiffs claimed Illumina fraudulently obtained two US patents by concealing a reference from the patent office.

BGI will have a chance to depose up to nine inventors of patents assigned to Illumina as part of a lawsuit over IP related to sequencing-by-synthesis chemistry.

A US District Court will prevent BGI from distributing and promoting certain sequencing instruments that allegedly infringe Illumina patents.

Illumina had argued that Complete Genomics' patent covering two-color sequencing-by-synthesis chemistry was obvious, but the US PTAB disagreed.

The researchers said a functional investigation of the virus' unknown transcripts and RNA modifications will elucidate its life cycle and pathogenicity.

Under the terms of the non-exclusive agreement, the companies have made Diagenode's D-Plex library preparation products available on MGI's sequencing platforms.

According to the complaint, the allegedly infringing products include all those that use nucleotides with a 3’-O-azidomethyl blocking group.